Clinical Trial Detail

NCT ID NCT03024216
Title Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Hawaii
Indications

prostate adenocarcinoma

Therapies

Atezolizumab + Sipuleucel-T

Age Groups: adult senior

No variant requirements are available.